The purpose of this study is to determine the risks of acquiring hepatitis C virus (HCV) infection associated with specific injection practices in a cohort of young, high-risk injection drug users (IDUs) on the Lower East Side of Manhattan, and the possible protective effect of pre-existing HCV-specific immune responses. Hepatitis C is the most rapidly rising opportunistic infection in persons with human immunodeficiency virus (HIV) infection and already the leading cause of death in persons with HIV/HCV co-infection. Because it is more prevalent and more readily transmitted among IDUs than HIV, HCV prevention serves as a sensitive model for the prevention of HIV and other bloodborne infections among IDUs. Despite advances in our understanding of HCV and its transmission, HCV continues to spread rapidly among IDUs, who now account for most new HCV infections in the developed world. A better understanding of the risks associated with the sharing of syringes and other injection equipment and many other opportunities for blood contact that arise during the preparation and injection of drugs is needed to guide the development of more effective prevention interventions. The proposed study will interview 100 high-risk, HCV-uninfected IDUs every two weeks and collect detailed information about their injection practices in order to examine the risks associated with specific injection practices.
The specific aims are to: (1) Determine the specific injection practices associated with an increased risk of HCV infection, and estimate for each (a) the magnitude of the risk, (b) the dose-response relationship, and (c) the per-act transmission rate;(2) Examine how a prolonged period of frequent interaction with a research interviewer affects the relative performance of interviewer- vs. computer- administered questions;(3) Examine the impact of certain contextual factors characterizing injection settings on injection practices and HCV transmission;and (4) 4. Examine whether HCV-specific cellular immune responses observed in subjects at baseline exert a protective effect, and estimate the strength of any such effect. The findings from this study will help guide the development of evidence-based HCV prevention interventions, permit more accurate modeling of the HCV epidemic, and enhance our understanding of HCV- specific immunity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA021550-05
Application #
8262397
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Comolli, Jean C
Project Start
2008-06-01
Project End
2012-12-07
Budget Start
2012-06-01
Budget End
2012-12-07
Support Year
5
Fiscal Year
2012
Total Cost
$179,516
Indirect Cost
$54,650
Name
Suny Downstate Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
040796328
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Edlin, Brian R; Winkelstein, Emily R (2014) Can hepatitis C be eradicated in the United States? Antiviral Res 110:79-93
Duggal, Priya; Thio, Chloe L; Wojcik, Genevieve L et al. (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158:235-45
Raghuraman, Sukanya; Park, Heiyoung; Osburn, William O et al. (2012) Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 205:763-71
Zeremski, Marija; Hooker, Giles; Shu, Marla A et al. (2011) Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 55:545-53
Dias, Paulo Telles; Hahn, Judith A; Delwart, Eric et al. (2011) Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 11:208
Edlin, Brian R; Shu, Marla A; Winkelstein, Emily et al. (2009) More rare birds, and the occasional swan. Gastroenterology 136:2412-4
Zeremski, M; Shu, M A; Brown, Q et al. (2009) Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 16:10-20
Weiss, J J; Bhatti, L; Dieterich, D T et al. (2008) Hepatitis C patients'self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther 28:289-93
Kuntzen, Thomas; Timm, Joerg; Berical, Andrew et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-78
Page-Shafer, Kimberly; Pappalardo, Brandee L; Tobler, Leslie H et al. (2008) Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol 46:499-506

Showing the most recent 10 out of 12 publications